These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 23478143)
1. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer. Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. Li Y; Sun J; Jiang Z; Zhang L; Liu G J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948 [TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Kasuga A; Okano N; Naruge D; Kitamura H; Takasu A; Nagashima F; Furuse J Cancer Chemother Pharmacol; 2015 Mar; 75(3):457-64. PubMed ID: 25547407 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Sudo K; Ishihara T; Hirata N; Ozawa F; Ohshima T; Azemoto R; Shimura K; Nihei T; Nishino T; Nakagawa A; Nakamura K; Hara T; Tada M; Mikata R; Tawada K; Yokosuka O; Nakaji S; Yamaguchi T Cancer Chemother Pharmacol; 2014 Feb; 73(2):389-96. PubMed ID: 24322377 [TBL] [Abstract][Full Text] [Related]
6. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034 [TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537 [TBL] [Abstract][Full Text] [Related]
12. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer. Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537 [TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961 [TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. Nakata B; Amano R; Nakao S; Tamura T; Shinto O; Hirakawa T; Okita Y; Yamada N; Hirakawa K J Exp Clin Cancer Res; 2010 Feb; 29(1):15. PubMed ID: 20181235 [TBL] [Abstract][Full Text] [Related]
16. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile. Liu Y; Huang QK; Hong WD; Wu JM; Sun XC Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193 [TBL] [Abstract][Full Text] [Related]
17. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351 [TBL] [Abstract][Full Text] [Related]
18. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer]. Miyagawa K; Yata Y; Yamaoka N; Sagara Y Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K Oncology; 2005; 69(5):421-7. PubMed ID: 16319514 [TBL] [Abstract][Full Text] [Related]
20. [Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer]. Takahata T; Sato A; Yu C; Saito K Gan To Kagaku Ryoho; 2018 May; 45(5):817-821. PubMed ID: 30026444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]